je.st
news
New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA (sitagliptin) Will Be Presented at the European Society of Cardiology Congress
2015-08-20 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Additional Real-World Analyses from DYSIS and DYSIS II Assessing the Treatment of Dyslipidemia to be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new analyses from the investigational IMPROVE-IT (IMProved Reduction of Outcomes: VYTORIN Efficacy International Trial) study of VYTORIN (ezetimibe and simvastatin), the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) cardiovascular safety trial of JANUVIA (sitagliptin), and real-world data from the Dyslipidemia International Study (DYSIS I and DYSIS II) will be presented at the upcoming European Socie Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-391-0131orInvestor:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
of
will
study
Category:Biotechnology and Pharmaceuticals